Simultaneous inhibition of PD-L1 and TGFβ, by using a bifunctional fusion protein, effectively reverted the mesenchymalization and chemotherapy resistance of human lung cancer cells (7), which highlights the possible benefit of addressing both, the tumor as well as infiltrating immune cells. The gene discussed is TGFB1; the disease is lung carcinoma.